These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 38784952)
1. BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics Canella A; Nazzaro M; Artomov M; Rao Venkata LP; Thomas D; Lyberger J; Ukhatov A; Xing YL; Miller K; Behbehani G; Amankulor NM; Petritsch CK; Rajappa P Mol Ther Oncol; 2024 Jun; 32(2):200808. PubMed ID: 38784952 [TBL] [Abstract][Full Text] [Related]
2. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518 [TBL] [Abstract][Full Text] [Related]
9. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234 [TBL] [Abstract][Full Text] [Related]
10. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship. Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. Thompson EM; Landi D; Ashley D; Keir ST; Bigner D J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661 [TBL] [Abstract][Full Text] [Related]
12. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440 [TBL] [Abstract][Full Text] [Related]
13. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study. Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866 [TBL] [Abstract][Full Text] [Related]
16. Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature. Vermeulen E; Vander Mijnsbrugge AS; Brock S; Vaeyens F; Dirven I; Ciçek A; Marcelis W; Klein S; Bruneau M; Neyns B; Duerinck J Case Rep Oncol; 2024; 17(1):10-16. PubMed ID: 38179547 [TBL] [Abstract][Full Text] [Related]
17. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331 [TBL] [Abstract][Full Text] [Related]
18. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767 [TBL] [Abstract][Full Text] [Related]
19. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358 [TBL] [Abstract][Full Text] [Related]
20. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma. Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]